BRPI0411563A - uso para derivados de estaurosporina - Google Patents

uso para derivados de estaurosporina

Info

Publication number
BRPI0411563A
BRPI0411563A BRPI0411563-5A BRPI0411563A BRPI0411563A BR PI0411563 A BRPI0411563 A BR PI0411563A BR PI0411563 A BRPI0411563 A BR PI0411563A BR PI0411563 A BRPI0411563 A BR PI0411563A
Authority
BR
Brazil
Prior art keywords
derivatives
staurosporine
warm
staurosporine derivatives
allergy
Prior art date
Application number
BRPI0411563-5A
Other languages
English (en)
Inventor
Steven Coutre
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33539193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0411563(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0411563A publication Critical patent/BRPI0411563A/pt
Publication of BRPI0411563B1 publication Critical patent/BRPI0411563B1/pt
Publication of BRPI0411563B8 publication Critical patent/BRPI0411563B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"USO PARA DERIVADOS DE ESTAUROSPORINA". A presente invenção refere-se ao uso dos derivados de estaurosporinas para tratamento curativo, paliativo ou profilático de rinite alérgica, dermatite alérgica, alergia aos fármacos ou alergia aos alimentos, angioedema, urticária, síndrome de morte súbita infantil, aspergilose broncopulmonar, esclerose múltipla ou mastocitose; e a um processo para tratamento de animais de sangue quente, onde uma dose terapeuticamente de um composto de um Derivado de Estaurosporina é administrada a um animal de sangue quente que sofre de uma das doenças ou condições mencionadas acima.
BRPI0411563A 2003-06-18 2004-06-17 uso de n-[(9s, 10r, 11r, 13r)-2,3,10,11,12,13-hexahidro-10-metóxi-9-metil-1-oxo-9,13-epóxi-1h,9h-iindol[1,2,3-gh:3',2',1'-lm]pirrol[3,4-j][1,7]benzodiazonin-11-il]-nmetilbenzamida BRPI0411563B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47957503P 2003-06-18 2003-06-18
US60/479,575 2003-06-18
PCT/EP2004/006562 WO2004112794A2 (en) 2003-06-18 2004-06-17 New pharmaceutical uses of staurosporine derivatives

Publications (3)

Publication Number Publication Date
BRPI0411563A true BRPI0411563A (pt) 2006-08-01
BRPI0411563B1 BRPI0411563B1 (pt) 2019-09-24
BRPI0411563B8 BRPI0411563B8 (pt) 2021-05-25

Family

ID=33539193

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411563A BRPI0411563B8 (pt) 2003-06-18 2004-06-17 uso de n-[(9s, 10r, 11r, 13r)-2,3,10,11,12,13-hexahidro-10-metóxi-9-metil-1-oxo-9,13-epóxi-1h,9h-iindol[1,2,3-gh:3',2',1'-lm]pirrol[3,4-j][1,7]benzodiazonin-11-il]-nmetilbenzamida

Country Status (23)

Country Link
US (2) US8575146B2 (pt)
EP (1) EP1638574B1 (pt)
JP (2) JP5057780B2 (pt)
CN (2) CN100457111C (pt)
AT (1) ATE464052T1 (pt)
AU (1) AU2004248909B2 (pt)
BE (1) BE2017C067I2 (pt)
BR (1) BRPI0411563B8 (pt)
CA (2) CA2785950A1 (pt)
CY (2) CY1110179T1 (pt)
DE (1) DE602004026578D1 (pt)
DK (1) DK1638574T3 (pt)
ES (1) ES2344700T3 (pt)
FR (1) FR17C1063I2 (pt)
HU (1) HUS000503I2 (pt)
LU (1) LUC00055I9 (pt)
MX (1) MXPA05013722A (pt)
NL (1) NL300917I2 (pt)
PL (1) PL1638574T3 (pt)
PT (1) PT1638574E (pt)
SI (1) SI1638574T1 (pt)
TW (1) TWI324604B (pt)
WO (1) WO2004112794A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
JP4762150B2 (ja) 2003-11-18 2011-08-31 ノバルティス アーゲー Ｋｉｔの変異体の阻害剤
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
AU2005274852B2 (en) * 2004-07-19 2011-12-08 The Johns Hopkins University FLT3 inhibitors for immune suppression
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
CN101171013A (zh) * 2005-05-02 2008-04-30 诺瓦提斯公司 嘧啶基氨基苯甲酰胺衍生物用于治疗全身性肥大细胞增多症的应用
DE602006013826D1 (de) * 2005-07-20 2010-06-02 Peter Valent Zusammensetzungen zur behandlung von systemischer mastocytose
CA2629478C (en) * 2005-11-14 2013-10-15 Universitat Zurich Staurosporine derivatives for use in alveolar rhabdomyosarcoma
WO2009092442A1 (en) * 2008-01-23 2009-07-30 Universidad De Barcelona Treatment of portal hypertension and related conditions by combined inhibition of the vegf and pdgf signalling pathways
EP2637650A2 (en) * 2010-11-10 2013-09-18 National Jewish Health Methods to test allergic conditions
AU2019374142A1 (en) 2018-11-01 2021-05-27 Syros Pharmaceuticals, Inc. Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (CDK7)
US11325978B2 (en) * 2018-11-06 2022-05-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for treating beta-globinopathies
US11839619B2 (en) * 2019-09-16 2023-12-12 The Regents Of The University Of California Methods for treatment of pediatric systemic mastocytosis
KR102805013B1 (ko) * 2022-03-15 2025-05-09 국립해양생물자원관 스트렙토마이세스 속 snc087 균주 또는 이로부터 분리한 스타우로스포린을 유효성분으로 포함하는 비용종 예방 또는 치료용 약학 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639455A (en) * 1984-10-02 1987-01-27 Key Pharmaceuticals, Inc. Means of aiding in the prevention of sudden infant death syndrome
JPH0826037B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
DE69229490T2 (de) * 1991-05-09 2000-02-17 Neurim Pharmaceuticals (1991) Ltd., Tel Aviv Melatonin enthaltende Arzneimittel
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
US6184217B1 (en) * 1996-06-25 2001-02-06 Cephalon, Inc. Use of K-252a derivative
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
WO1999062537A1 (en) 1998-06-04 1999-12-09 The Rockefeller University Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
CA2431187A1 (en) 2000-12-08 2002-06-13 Ortho-Mcneil Pharmaceutical, Inc. Macroheterocylic compounds useful as kinase inhibitors
GB0108606D0 (en) 2001-04-05 2001-05-23 Novartis Ag Organic compounds
DE60227709D1 (de) * 2001-06-29 2008-08-28 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
CN101703509A (zh) * 2001-10-30 2010-05-12 诺瓦提斯公司 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
EP1645286A1 (en) * 2003-04-18 2006-04-12 Kyowa Hakko Kogyo Co., Ltd. Drug for nerve regeneration
US20070037882A1 (en) * 2003-04-22 2007-02-15 Astellas Pharma Inc. Remedy for cerebral neurodegenerative diseases using ppar agonist
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
JP4762150B2 (ja) 2003-11-18 2011-08-31 ノバルティス アーゲー Ｋｉｔの変異体の阻害剤

Also Published As

Publication number Publication date
CN1805749A (zh) 2006-07-19
FR17C1063I2 (fr) 2019-05-03
CY2017048I2 (el) 2018-09-05
JP2012144572A (ja) 2012-08-02
US8575146B2 (en) 2013-11-05
HUS1700053I1 (hu) 2018-01-29
JP2006527727A (ja) 2006-12-07
BRPI0411563B8 (pt) 2021-05-25
JP5057780B2 (ja) 2012-10-24
PT1638574E (pt) 2010-07-14
WO2004112794A2 (en) 2004-12-29
EP1638574B1 (en) 2010-04-14
CA2527703C (en) 2012-10-23
LUC00055I1 (pt) 2017-12-14
WO2004112794A3 (en) 2005-06-16
LUC00055I2 (pt) 2018-02-21
CY1110179T1 (el) 2015-01-14
FR17C1063I1 (pt) 2018-02-16
TW200512213A (en) 2005-04-01
SI1638574T1 (sl) 2010-08-31
EP1638574A2 (en) 2006-03-29
AU2004248909B2 (en) 2008-05-08
BRPI0411563B1 (pt) 2019-09-24
HK1095519A1 (zh) 2007-05-11
CN101164539A (zh) 2008-04-23
ATE464052T1 (de) 2010-04-15
NL300917I2 (nl) 2018-01-09
CY2017048I1 (el) 2018-09-05
DK1638574T3 (da) 2010-08-02
CN100457111C (zh) 2009-02-04
TWI324604B (en) 2010-05-11
LUC00055I9 (pt) 2022-11-09
AU2004248909A1 (en) 2004-12-29
PL1638574T3 (pl) 2010-09-30
BE2017C067I2 (pt) 2023-08-09
HUS000503I2 (hu) 2021-03-29
CA2785950A1 (en) 2004-12-29
US20130289018A1 (en) 2013-10-31
ES2344700T3 (es) 2010-09-03
MXPA05013722A (es) 2006-03-08
CA2527703A1 (en) 2004-12-29
US20070299049A1 (en) 2007-12-27
NL300917I1 (nl) 2017-12-12
DE602004026578D1 (de) 2010-05-27

Similar Documents

Publication Publication Date Title
FR17C1063I2 (fr) Nouvelle utilisation de derives de staurosporine
DK1611088T3 (da) Hydroxymater som terapeutiske midler
EP1539234A4 (en) METHOD FOR PREVENTING OR TREATING CELL MALIGNITY BY ADMINISTERING CD2 ANTAGONISTS
BRPI0509576A (pt) composto, método de tratamento de um paciente tendo uma condição que é mediada pela atividade de proteìna quinase, e, composição farmacêutica
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
EA200971053A1 (ru) Способы лечения кожных язв
BRPI0409888A (pt) derivados de pirazol como inibidores de fosfodiesterase 4, composto, composição farmacêutica, método para efetuar a inibição da enzima pde4, incrementar a cognição e/ou tratar a psicose em um paciente, método para o tratamento de um paciente que tem uma doença que envolve nìveis de camp diminuìdos, método para o tratamento de um paciente que sofre de uma doença alérgica ou inflamatória e método para o tratamento de um paciente que sofre de neurodegeneração resultante de uma doença ou de um ferimento
BRPI0410170A (pt) preparação e uso de derivados de ácido aril alquìlico para o tratamento de obesidade
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
BR0311931A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença ou condição mediada com hppar em um paciente
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
BR112022025946A2 (pt) Composto, composição farmacêutica e método de tratamento de uma doença
BR0208663A (pt) Uso de derivados de n-fenil-2-pirimidina-amina contra doenças com base em mastócito tal como distúrbios alérgicos
BRPI1008103A2 (pt) " peptídeo de cadeia curta isolado, composição farmacêutica, compostos, método de evitar ou tratar doenças, medicamento para tratar/ reduzir condições médicas e uso dos compostos "
NO952601L (no) Oligonukleotider for inhibering av ekspresjon av isoprenylprotein-transferaser
BR0209787A (pt) Compostos, processo para a preparação dos mesmos, composição farmacêutica, métodos de tratamento de um paciente humano ou animal que sofre de uma condição que é mediada por cox-2 e que sofre de um distúrbio inflamatório, e, uso de um composto
BR0313503A (pt) Método de tratamento de sìndrome das pernas inquietas, uso do antagonista de receptor da adenoina a2a, agente terapêutico para sìndrome das pernas inquietas, e, método de tratamento da mioclonia noturna
BRPI0517084A (pt) composto de éster, composição farmacêutica, inibidor da proteìna de transferência de triglicerìdeo microssÈmico, agente de diminuição de pelo menos um dos parámetros lipìdicos do sangue, método para o tratamento ou profilaxia de uma doença, embalagem comercial, e, uso do composto de éster
TH401002069A (th) การใช้แบบใหม่ของอนุพันธ์สเทาโรสพอรีน
BR0315376A (pt) Combinações de benzotiadiazóis e inibidores de cox-2 para o tratamento de dor
EA200900313A1 (ru) Производные бензо[1,2,3]тиадиазина
TH16370A (th) สารประกอบไดแอริล

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09T Decision of refusal: decision cancelled [chapter 9.2.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/06/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2831 DE 08-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.